Shattuck Labs, Inc. 8-K

What Happened
Shattuck Labs, Inc. (STTK) announced on January 22, 2026 that it entered into a sales agreement with Leerink Partners LLC to sell, from time to time, up to $75,000,000 of its common stock in an at-the-market offering. The offering is registered on the Company’s Form S-3 (File No. 333-292697), which was declared effective by the SEC on January 21, 2026, with a prospectus supplement filed January 22, 2026.

Key Details

• Offering type: at-the-market sales through Leerink Partners LLC (sales agent).
• Maximum amount: up to $75,000,000 of common stock registered under the Form S-3.
• Agent fees and expenses: company will pay the agent up to 3.0% commission on gross sales and reimburse certain agent expenses.
• Use of proceeds: to advance clinical trials and additional product candidates, and for working capital and general corporate purposes.
• Other terms: Company has no obligation to sell shares, may suspend or terminate the agreement, and the agent may terminate in certain circumstances (e.g., material adverse effect). Gibson, Dunn & Crutcher LLP provided a legal opinion on the validity of the shares.

Why It Matters
This filing gives Shattuck Labs flexibility to raise up to $75M of capital by selling shares into the market over time, which can fund clinical programs and general operations. If the company sells shares, it will increase the outstanding share count and therefore dilute existing shareholders; the timing, amount and market impact depend on whether and how much the company chooses to sell under the agreement. Investors should watch for follow-up filings or press releases reporting actual sales, amounts raised, and any material changes to the sales agreement.